About US
Contact us
-
Promising growth next year, Viatris names Celgene vet Scott Smith its next CEOViatris CEO Michael Goettlerguided the company through a period of turbulence and change over the last several years. Now, he's getting ready to handover the reins. Viatrisis tappingbiopharma vete2023/2/21
-
COVID-19 tracker: Lab leak likely caused pandemic, US Energy Department saysvAfter reviewing new intelligence, the U.S. Energy Department has concluded that a lab leak in China likely caused the pandemic. But officials told The New York Times the agency had "low confidence" a2023/2/21
-
Galapagos' Jyseleca flops phase 3 Crohn's study, dealing another blow to troubled JAK inhibitorAfter a phase 3 trial flop, Galapagos’ JAK1 preferential inhibitor filgotinib won't be launching in Crohn’s disease anytime soon. The drug, branded as Jyselecain Europe, has had a rough g2023/2/17
-
Docs likely to be 'cautious' when prescribing GSK's first-in-class anemia drug Jesduvroq, survey findsThe path to approval was long and winding for a new class of medicines calledhypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors. And even afterGSK clinched regulatory victory earlier thi2023/2/17
-
Eli Lilly's employment decisions under fire once again as sales rep lodges age discrimination claimNot even six months after the U.S. Equal Employment Opportunity Commission sued Eli Lilly over alleged age bias, the company is at the center of another discrimination lawsuit. Monica Ric2023/2/15
-
GSK's unusual Jemperli expansion plan wins FDA panel backing—with a twistDuring a heated discussion around a potential GSK application for Jemperli in a rare cancer type, a panel of the FDA's external advisers largely took the middle ground between the company and the reg2023/2/15
-
Nearing FDA approval anniversary, Phathom gets more bad news on Voquezna impuritiesAs Phathom Pharmaceuticals approaches the one-year anniversary ofVoquezna's FDA approval to treat Helicobacter pylori infection, the regulatory blows keep coming. Late this week, Phathom2023/2/13
-
Roche's Vabysmo shows an edge over Regeneron's Eylea in retina dryingNew data from a phase 3 trial measuring Roche’s Vabysmo versus Regeneron and Bayer’s Eylea in retinal vein occlusion (RVO)showsthat more patients on Vabysmo had an absence of blood vessel leakage in2023/2/13
-
ABPI president, a Novo Nordisk exec, steps down after company's code breachesAfter Novo Nordisk breached not one, not two, but seven clauses of the code that regulates U.K. drugmakers, its U.K. general manager is stepping down as president of the industry's national organizat2023/2/9
-
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned downIn a tight BCMA CAR-T race, Bristol Myers Squibb has delivered the drug class’s first randomized trial win in multiple myeloma. But the detailed data, recently rejected by the American Society of Hem2023/2/9